Corcept Therapeutics (NASDAQ:CORT) Upgraded at Truist Financial

Posted by Francis Steltz on Jun 16th, 2026

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) was upgraded by equities research analysts at Truist Financial to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

CORT has been the topic of several other research reports. Piper Sandler upped their price objective on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the company an “overweight” rating in a research note on Friday, May 1st. Zacks Research raised shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 4th. HC Wainwright boosted their price target on Corcept Therapeutics from $75.00 to $95.00 and gave the company a “buy” rating in a report on Tuesday, June 2nd. Canaccord Genuity Group increased their price target on Corcept Therapeutics from $110.00 to $135.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Finally, UBS Group set a $135.00 price objective on Corcept Therapeutics in a report on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $88.83.

Get Our Latest Report on CORT

Corcept Therapeutics Trading Up 0.3%

Shares of CORT stock opened at $83.12 on Monday. The company has a market capitalization of $8.92 billion, a price-to-earnings ratio of 237.49 and a beta of 0.50. The firm has a 50-day moving average price of $56.51 and a 200 day moving average price of $52.10. Corcept Therapeutics has a twelve month low of $28.66 and a twelve month high of $91.00.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.19). The firm had revenue of $164.90 million for the quarter, compared to analyst estimates of $185.83 million. Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.Corcept Therapeutics’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the prior year, the business earned $0.17 earnings per share. As a group, research analysts predict that Corcept Therapeutics will post 0.62 earnings per share for the current year.

Insider Buying and Selling at Corcept Therapeutics

In related news, insider Sean Maduck sold 75,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $65.59, for a total value of $4,919,250.00. Following the sale, the insider directly owned 8,977 shares of the company’s stock, valued at approximately $588,801.43. This trade represents a 89.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Atabak Mokari sold 40,000 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $70.00, for a total transaction of $2,800,000.00. Following the completion of the sale, the chief financial officer owned 15,257 shares of the company’s stock, valued at approximately $1,067,990. The trade was a 72.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 242,965 shares of company stock worth $14,802,964. 20.70% of the stock is currently owned by insiders.

Institutional Trading of Corcept Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Parallel Advisors LLC raised its position in shares of Corcept Therapeutics by 2.5% in the 1st quarter. Parallel Advisors LLC now owns 3,977,404 shares of the biotechnology company’s stock worth $160,329,000 after buying an additional 96,763 shares during the period. State Street Corp grew its position in Corcept Therapeutics by 0.5% during the fourth quarter. State Street Corp now owns 2,986,056 shares of the biotechnology company’s stock valued at $103,915,000 after acquiring an additional 15,656 shares during the period. Geode Capital Management LLC increased its stake in Corcept Therapeutics by 38.0% during the fourth quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after acquiring an additional 734,646 shares during the last quarter. First Trust Advisors LP increased its stake in Corcept Therapeutics by 213.5% during the first quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock worth $87,609,000 after acquiring an additional 1,480,059 shares during the last quarter. Finally, Morgan Stanley raised its holdings in shares of Corcept Therapeutics by 34.1% in the 4th quarter. Morgan Stanley now owns 1,592,059 shares of the biotechnology company’s stock worth $55,404,000 after purchasing an additional 405,081 shares during the period. 93.61% of the stock is currently owned by institutional investors and hedge funds.

Corcept Therapeutics Company Profile

(Get Free Report)

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.